Pharmacology of ADP-ribosylation.

Abstract

ADP-ribosyltransferase ARTD1/PARP1 is a target for cancer and ischemia drug development. Several other ARTD-family enzymes have been characterized in recent years, and it has become clear that their inhibition might also have therapeutic value. This minireview series summarizes current knowledge of pharmacological inhibition of ADP-ribosyltransferases by a compound class called PARP inhibitors and the prospects for drug development.

• Authors: Herwig Schüler, Mathias Ziegler
• Journal: The FEBS journal (FEBS J) Vol. 280 Issue 15 Pg. 3542 (Aug 2013) ISSN: 1742-4658 [Electronic] England
• PMID: 23763848 (Publication Type: Introductory Journal Article)
• Copyright: © 2013 FEBS.

Chemical References

• Poly(ADP-ribose) Polymerase Inhibitors
• Adenosine Diphosphate Ribose
• Poly(ADP-ribose) Polymerases

Topics

• Adenosine Diphosphate Ribose (metabolism)
• Humans
• Ischemia (drug therapy)
• Molecular Targeted Therapy
• Neoplasms (drug therapy)
• Poly(ADP-ribose) Polymerase Inhibitors
• Poly(ADP-ribose) Polymerases (metabolism)
• Protein Processing, Post-Translational (drug effects)